Clinical Trial Update: Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089) [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating efficacy, safety, and pharmacokinetics of sugammadex for reversing neuromuscular blockade in pediatric participants.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromuscular Blockade

Drugs mentioned

• Sugammadex (sugammadex)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Neuromuscular Blockade | Phase 4 | Status: COMPLETED | Results posted: 2021-02-05